Alaunos Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Alaunos Therapeutics, Inc. (TCRT) reported Net Income (Loss) Available to Common Stockholders, Basic of -$988.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-14
- Alaunos Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$988.00K.
- Alaunos Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$1.16M.
- Alaunos Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$937.00K.
- Alaunos Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$1.20M.
- Alaunos Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$4.28M.
- Alaunos Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$4.68M.
- Alaunos Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$78.75M.
- Alaunos Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$79.98M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$988.00K 10-Q · filed 2026-08-14 | -$2.03M 10-Q · filed 2026-08-14 | -$3.08M derived: sum of 3 quarters · filed 2026-08-14 | -$4.28M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$1.16M 10-Q · filed 2026-05-15 | -$2.09M derived: sum of 2 quarters · filed 2026-05-15 | -$3.29M derived: sum of 3 quarters · filed 2026-05-15 | -$4.36M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$937.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$2.14M derived: sum of 2 quarters · filed 2026-03-31 | -$3.20M derived: sum of 3 quarters · filed 2026-08-14 | -$4.28M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$1.20M 10-Q · filed 2025-11-14 | -$2.27M derived: sum of 2 quarters · filed 2026-08-14 | -$3.35M 10-Q · filed 2025-11-14 | -$4.08M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$1.06M 10-Q · filed 2026-08-14 | -$2.14M 10-Q · filed 2026-08-14 | -$2.88M derived: sum of 3 quarters · filed 2026-08-14 | -$4.01M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$1.07M 10-Q · filed 2026-05-15 | -$1.81M derived: sum of 2 quarters · filed 2026-05-15 | -$2.94M derived: sum of 3 quarters · filed 2026-05-15 | |
| 2024-12-31 | -$742.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$1.87M derived: sum of 2 quarters · filed 2026-03-31 | -$4.68M 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$1.13M 10-Q · filed 2025-11-14 | -$3.94M 10-Q · filed 2025-11-14 | ||
| 2022-06-30 | -$9.93M 10-Q · filed 2022-08-15 | -$19.72M 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | -$9.79M 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | -$78.75M 10-K · filed 2022-03-30 | |||
| 2021-06-30 | -$22.67M 10-Q · filed 2022-08-15 | -$44.22M 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | -$21.55M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | -$79.98M 10-K · filed 2022-03-30 | |||
| 2019-12-31 | -$15.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$89.74M derived: sum of 2 quarters · filed 2021-03-01 | -$104.36M derived: sum of 3 quarters · filed 2021-03-01 | -$117.80M 10-K · filed 2021-03-01 |
| 2019-09-30 | -$74.00M 10-Q · filed 2019-11-07 | -$88.62M derived: sum of 2 quarters · filed 2019-11-07 | -$102.05M 10-Q · filed 2019-11-07 | $92.49M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$14.62M 10-Q · filed 2019-08-08 | -$28.05M 10-Q · filed 2019-08-08 | $166.48M derived: sum of 3 quarters · filed 2021-03-01 | $147.82M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$13.43M 10-Q · filed 2019-05-08 | $181.10M derived: sum of 2 quarters · filed 2021-03-01 | $162.44M derived: sum of 3 quarters · filed 2021-03-01 | $144.95M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $194.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $175.88M derived: sum of 2 quarters · filed 2021-03-01 | $158.39M derived: sum of 3 quarters · filed 2021-03-01 | $137.25M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$18.66M 10-Q · filed 2019-11-07 | -$36.15M derived: sum of 2 quarters · filed 2019-11-07 | -$57.29M 10-Q · filed 2019-11-07 | -$75.56M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$17.49M 10-Q · filed 2019-08-08 | -$38.63M 10-Q · filed 2019-08-08 | -$56.91M derived: sum of 3 quarters · filed 2020-03-02 | -$74.51M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$21.14M 10-Q · filed 2019-05-08 | -$39.41M derived: sum of 2 quarters · filed 2020-03-02 | -$57.02M derived: sum of 3 quarters · filed 2020-03-02 | -$74.74M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | -$18.27M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$35.88M derived: sum of 2 quarters · filed 2020-03-02 | -$53.60M derived: sum of 3 quarters · filed 2020-03-02 | -$73.26M 10-K · filed 2020-03-02 |
| 2017-09-30 | -$17.60M 10-Q · filed 2018-11-09 | -$35.33M derived: sum of 2 quarters · filed 2018-11-09 | -$54.99M 10-Q · filed 2018-11-09 | -$69.75M derived: sum of 4 quarters · filed 2019-03-05 |
| 2017-06-30 | -$17.73M 10-Q · filed 2018-08-08 | -$37.38M 10-Q · filed 2018-08-08 | -$52.14M derived: sum of 3 quarters · filed 2019-03-05 | -$66.59M derived: sum of 4 quarters · filed 2019-03-05 |
| 2017-03-31 | -$19.66M 10-Q · filed 2018-05-10 | -$34.41M derived: sum of 2 quarters · filed 2019-03-05 | -$48.86M derived: sum of 3 quarters · filed 2019-03-05 | -$180.06M derived: sum of 4 quarters · filed 2019-03-05 |
| 2016-12-31 | -$14.76M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | -$29.20M derived: sum of 2 quarters · filed 2019-03-05 | -$160.40M derived: sum of 3 quarters · filed 2019-03-05 | -$172.42M 10-K · filed 2019-03-05 |
| 2016-09-30 | -$14.45M 10-Q · filed 2017-11-06 | -$145.65M derived: sum of 2 quarters · filed 2017-11-06 | -$157.66M 10-Q · filed 2017-11-06 | -$167.14M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | -$131.20M 10-Q · filed 2017-07-31 | -$143.22M 10-Q · filed 2017-07-31 | -$152.69M derived: sum of 3 quarters · filed 2018-03-01 | -$170.87M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | -$12.02M 10-Q · filed 2017-05-01 | -$21.50M derived: sum of 2 quarters · filed 2018-03-01 | -$39.66M derived: sum of 3 quarters · filed 2018-03-01 | |
| 2015-12-31 | -$9.48M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$27.65M derived: sum of 2 quarters · filed 2018-03-01 | -$120.09M 10-K · filed 2018-03-01 | |
| 2015-09-30 | -$18.17M 10-Q · filed 2016-11-09 | -$110.61M 10-Q · filed 2016-11-09 | ||
| 2014-12-31 | -$31.78M 10-K · filed 2017-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |